Form 4: Neurogene CSO Stuart Cobb Receives RSU Grant

Neurogene Inc.'s Chief Scientific Officer, Stuart Cobb, was granted 16,500 restricted stock units, increasing his total beneficial ownership to 37,294 units.

Summary

• Stuart Cobb, Chief Scientific Officer of Neurogene Inc., acquired 16,500 restricted stock units (RSUs) on February 20, 2026.
• These RSUs were granted at a price of $0 and will vest in three equal annual installments, beginning on the first anniversary of the grant date, contingent on continued service.
• Following this transaction, Mr. Cobb beneficially owns a total of 37,294 restricted stock units.
• This total includes 13,594 RSUs remaining from a March 13, 2024 grant, 7,200 RSUs from a March 26, 2025 grant, and the newly granted 16,500 RSUs from February 20, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive compensation practices aimed at retaining key talent and aligning management's interests with long-term company performance.

Positives

• The grant of 16,500 restricted stock units to the Chief Scientific Officer indicates continued commitment to executive retention and aligns management's interests with long-term shareholder value.
• The vesting schedule over three years provides an incentive for Mr. Cobb to remain with Neurogene Inc. and contribute to its future success.

Negatives

• No specific negative information is contained within this Form 4 filing.

Risks

• The vesting of restricted stock units is contingent upon the reporting person's continued provision of services to the Issuer, meaning the units could be forfeited if employment ceases before vesting dates.

Future Outlook

NA

Management Comments

• Consist of 16,500 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units to a Chief Scientific Officer is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key talent. Such equity awards are crucial for aligning executive performance with long-term company growth and shareholder interests, especially in R&D-intensive sectors like Neurogene's.

Comparison to Industry Standards

• Executive compensation packages in the biotech sector frequently include significant equity components like RSUs, similar to those granted to Stuart Cobb.
• Companies such as Sarepta Therapeutics, Biogen, and Vertex Pharmaceuticals commonly utilize multi-year vesting schedules for executive equity awards to ensure long-term commitment and performance alignment.
• The three-year annual vesting schedule for Neurogene's RSUs is consistent with typical industry practices designed to foster executive retention and incentivize sustained contributions to drug development and scientific innovation.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Scientific Officer's interests with long-term shareholder value by incentivizing continued performance and retention.
• Employees: May signal stability in executive leadership and a commitment to retaining key personnel.

Next Steps

• The 16,500 restricted stock units will vest in three equal annual installments beginning on February 20, 2027, February 20, 2028, and February 20, 2029, subject to continued service.
• Other previously granted RSUs will continue to vest on their respective schedules (March 13, 2025, 2026, 2027 for the 2024 grant; March 26, 2026, 2027, 2028 for the 2025 grant).

Key Dates

Recommendation

This Form 4 filing details a routine restricted stock unit grant to a key executive, which is a standard component of executive compensation. While it signals executive retention and alignment, it does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should hold their position and look for more substantive corporate announcements.

Keywords

Neurogene Inc., NGNE, Stuart Cobb, Chief Scientific Officer, Restricted Stock Units, RSU grant, Insider Transaction, Executive Compensation, Form 4, Equity Award